Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies.

Rondy M, Kissling E, Emborg HD, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A, McMenamin J, Valenciano M; I-MOVE/I-MOVE+ group.

Euro Surveill. 2018 Mar;23(9). doi: 10.2807/1560-7917.ES.2018.23.9.18-00086.

2.

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.

Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, Rogalska J, Pitigoi D, Paradowska-Stankiewicz I, Reuss A, Jiménez-Jorge S, Daviaud I, Guiomar R, O'Donnell J, Necula G, Głuchowska M, Moren A.

Euro Surveill. 2014 Feb 13;19(6). pii: 20701.

3.

Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.

Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, Domegan L, Pitigoi D, Machado A, Paradowska-Stankiewicz IA, Bella A, Larrauri A, Ferenczi A; Joan O´Donell, Lazar M, Pechirra P, Korczyńska MR, Pozo F, Moren A; I-MOVE multicentre case-control team.

Euro Surveill. 2016;21(7):pii=30139. doi: 10.2807/1560-7917.ES.2016.21.7.30139. Erratum in: Euro Surveill. 2016;21(8). doi: 10.2807/1560-7917.ES.2016.21.8.30145.

4.
5.

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals.

Rondy M, Launay O, Puig-Barberà J, Gefenaite G, Castilla J, de Gaetano Donati K, Galtier F, Hak E, Guevara M, Costanzo S; European hospital IVE network, Moren A.

Euro Surveill. 2015 Jan 15;20(2). pii: 21011. Erratum in: Euro Surveill. 2015;20(3). pii: 21015. Niesters, Hubert [added].

6.

The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, Pitigoi D, Machado A, Pozo F; I-MOVE Multicentre Case Control Study Team.

Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28.

7.

Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.

Andrews N, McMenamin J, Durnall H, Ellis J, Lackenby A, Robertson C, von Wissmann B, Cottrell S, Smyth B, Moore C, Gunson R, Zambon M, Fleming D, Pebody R.

Euro Surveill. 2014 Jul 10;19(27):5-13.

8.

Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017.

Sullivan SG, Chilver MB, Carville KS, Deng YM, Grant KA, Higgins G, Komadina N, Leung VK, Minney-Smith CA, Teng D, Tran T, Stocks N, Fielding JE.

Euro Surveill. 2017 Oct;22(43). doi: 10.2807/1560-7917.ES.2017.22.43.17-00707.

9.

Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season.

Castilla J, Navascués A, Fernández-Alonso M, Reina G, Albéniz E, Pozo F, Álvarez N, Martínez-Baz I, Guevara M, García-Cenoz M, Irisarri F, Casado I, Ezpeleta C; Primary Health Care Sentinel Network and Network for Influenza Surveillance in Hospitals of Navarra.

Euro Surveill. 2016 Jun 2;20(22). doi: 10.2807/1560-7917.ES.2016.21.22.30243.

10.

Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results.

Pebody RG, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, Green HK, Cottrell S, Johnston J, de Lusignan S, Moore C, Gunson R, Robertson C, McMenamin J, Zambon M.

Euro Surveill. 2015 Feb 5;20(5):21025. No abstract available.

11.

2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children.

Kissling E, Valenciano M, Pozo F, Vilcu AM, Reuss A, Rizzo C, Larrauri A, Horváth JK, Brytting M, Domegan L, Korczyńska M, Meijer A, Machado A, Ivanciuc A, Višekruna Vučina V, van der Werf S, Schweiger B, Bella A, Gherasim A, Ferenczi A, Zakikhany K, O Donnell J, Paradowska-Stankiewicz I, Dijkstra F, Guiomar R, Lazar M, Kurečić Filipović S, Johansen K, Moren A; I-MOVE/I-MOVE+ study team.

Influenza Other Respir Viruses. 2018 Jul;12(4):423-437. doi: 10.1111/irv.12520. Epub 2018 Mar 14.

12.

Effectiveness of influenza vaccine in preventing medically-attended influenza virus infection in primary care, Israel, influenza seasons 2014/15 and 2015/16.

Yaron-Yakoby H, Sefty H, Pando R, Dichtiar R, Katz MA, Stein Y, Mandelboim M, Mendelson E, Shohat T, Glatman-Freedman A; The Israeli Influenza Surveillance Network (IISN).

Euro Surveill. 2018 Feb;23(7). doi: 10.2807/1560-7917.ES.2018.23.7.17-00026.

13.

Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019.

Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B.

MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):135-139. doi: 10.15585/mmwr.mm6806a2.

14.

Circulation of influenza A and B in the Czech Republic from 2000-2001 to 2015-2016.

Havlickova M, Druelles S, Jirincova H, Limberkova R, Nagy A, Rasuli A, Kyncl J.

BMC Infect Dis. 2019 Feb 14;19(1):160. doi: 10.1186/s12879-019-3783-z.

15.

Estimating vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings in South Africa, 2015.

McAnerney JM, Walaza S, Tempia S, Blumberg L, Treurnicht FK, Madhi SA, Valley-Omar Z, Cohen C.

Influenza Other Respir Viruses. 2017 Mar;11(2):177-181. doi: 10.1111/irv.12436. Epub 2016 Dec 20.

16.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, Krajden M, Bastien N, Li Y.

J Infect Dis. 2017 Dec 19;216(12):1487-1500. doi: 10.1093/infdis/jix526.

17.

Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.

Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM.

MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185. doi: 10.15585/mmwr.mm6706a2.

18.

Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.

Kissling E, Rondy M; I-MOVE/I-MOVE+ study team.

Euro Surveill. 2017 Feb 16;22(7). pii: 30464. doi: 10.2807/1560-7917.ES.2017.22.7.30464.

19.

Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017.

Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Foust A, Sessions W, Berman L, Spencer S, Fry AM.

MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):167-171. doi: 10.15585/mmwr.mm6606a3.

20.

Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study.

Savulescu C, Jiménez-Jorge S, de Mateo S, Ledesma J, Pozo F, Casas I, Larrauri A; cycEVA Study Team.

Euro Surveill. 2011 Mar 17;16(11). pii: 19820.

Supplemental Content

Support Center